For Laboratory Professionals
OncoDNA solutions solve problems faced by laboratories by driving efficiencies in workflows and automating reporting.
Our aim at OncoDNA is to help laboratories to scale Comprehensive Genomic Profiling (CGP) making it widely available. We provide a reliable and complete enrichment and library prep solution for performing NGS analysis of tumour samples in-house. Our software provides access to raw data or can create a simple clinically actionable report aimed at the oncologist.
For those periods when laboratory workforce is unavailable, or demand for testing peaks a ‘send away’ service using oncoDNA’s laboratory in Belgium is available as a ‘back up’.
In-house CE-IVD CGP solution
Effective Lab process
Low DNA/RNA input required
Pan-cancer molecular profiling
Rapid Turn Around Time
SNVs, CNVs, Fusion genes, unusual splicing, TMB, HRD, MSI
Up-to-date biomarker-matched therapy selection
Exportable QC and Variants data
Comprehensive report direct to the patient record
Scientific and Field application support
Data insights and management
Simple to automate
Streamline your Comprehensive Genomic Profiling laboratory process
OncoDNA brings a decade of oncology expertise directly into your laboratory with end-to-end solutions
Library preparation (3 hours)
Library preparation (3 hours)- DNA fragmentation, end repair & dA tailing.
- Ligate Twist universal adapters and purify.
- PCR amplify using Twist UDI Primers, purify and QC.
Target enrichment (20 hours)
- Prepare libraries for hybridization
- Hybridize capture probes
- Bind hybridized targets to streptavidin beads
- Post-capture PCR amplification, purify and QC
* only 4 hours of hands on
Sequencing (20 hours)
Sequencing (20 hours)Sequencing on Illumina NextSeq 500/550, NextSeq 1000/2000 or NovaSeq 6000, NovaSeq X, Element AVITI™ MGI sequencers
Analysis & interpretation (Up to 48 hours)
Analysis & interpretation (Up to 48 hours)- Upload FASTQ files
- Secondary and tertiary analysis via OncoDEEP pipeline
- OncoKDM: Personalized therapeutical interpretation
Fast and reliable interpretation of complex data with clinically actionable reporting
OndoKDM’s comprehensive interpretation reports provide laboratories with insight to enhance the understanding of NGS data, including detailed annotations, a list of actionable variants, a list of therapy recommendations and a summary of relevant clinical trials. The report is designed to be editable, facilitating pathology experts in incorporating observations before transferring the finalized report to oncologists.
Analysis details and quality control
Accurate and reliable clinical interpretation of genomic data is essential for labs. OncoKDM provides the necessary views to labs to ensure the quality of sequencing data by enabling them to control key values. However, if labs require a deeper insight into molecular data such as hotspots, they can utilize the advanced Mercury platform.
Watch the videoVariants detection
Our comprehensive variant analysis allows labs to discover all relevant variants detected through sequencing, which are categorized as SNV, INDEL, CNV, AMP. Additionally, we classify each variant based on its biological and therapeutic impact, using the TIER classification system that follows the established ACMG/AMP guidelines ensuring labs receive detailed and accurate information about each variant's potential clinical significance.
Watch the videoGenomic signatures
In addition to identifying individual alterations, the OncoDEEP kit also focuses on complex genomic signatures and rearrangements, such as HRD, MSI, and TM. Our process includes scoring and reporting the expression of these signatures into OncoKDM, enabling labs to access a comprehensive overview of their patients' molecular profile. By incorporating these signatures into the analysis, we provide a more complete picture of the tumor's biology ensuring the best clinical interpretation.
Watch the videoDrugs recommendation
OncoKDM treatment recommendation provides a clear overview of the most effective treatment options based on official guidelines and clinical evidence, ensuring that non-responders are spared from unnecessary toxicities and ineffective therapies. We list each drug with its associated biomarkers and approval details, allowing oncologists to make informed decisions about the best treatment for the patients.
Watch the videoClinical Trials
Easily find worldwide, relevant clinical trials that have reached at least Phase 2, based on your patient's specific condition and molecular profile. With our advanced search capabilities, you can quickly identify clinical trials that are most likely to benefit your patients and provide them with the latest treatment options available.
Watch the videoA comprehensive summary
Our comprehensive reporting includes key findings, simplified pathway analysis, and treatment recommendations based on both molecular and clinical evidence. This allows labs to easily understand the implications of the molecular profiling results and make informed decisions about the best course of treatment for the patients.
Watch the video
Extensive QC data visualization
Besides providing labs with QC data on sample quality such as read length and read quality,
OncoKDM also offers genomic information at both the sample and gene levels.
Scientific support at every stage of the process
OncoDNA’s scientific and medical teams support your laboratory along the entire implementation process
From initial setup to ongoing operations, OncoDNA provides tailored support to ensure a smooth integration of our cutting-edge technology. Our dedicated team offers:
- Technical Assistance: Our FAS (Field Application Support) provides expert guidance and support during the installation and configuration process, ensuring that labs can quickly get up and running with the OncoDEEP® Kit.
- Training Programs: Comprehensive training programs are available to laboratory staff, empowering them with the knowledge and skills needed to effectively utilize the OncoDEEP® Kit in their daily workflows.
- Dedicated Scientific Team: Our scientific team is available to provide assistance and address any questions or concerns that may arise, offering prompt and personalized support whenever it’s needed.
FAQ
How long does it take to receive my reports in OncoKDM?
Our Turnaround time is calculated from the sequencing data reception and their validation by OncoDNA to the release of the reports on both platforms. The usual TAT is up to 48h . two business days.
How long does it take to receive my reports in OncoKDM?
Our Turnaround time is calculated from the sequencing data reception and their validation by OncoDNA to the release of the reports on both platforms. The usual TAT is up to 48h . two business days.
How often does OncoDNA update its database?
Every night, our automated algorithm queries the world for new knowledge that does not exists on our database. Any new information will be reviewed by our science team before integrating to our knowledge database. Typically:
Variant information is updated every week
Drugs information is updated daily
Can I edit the report after it has been published in OncoKDM?
Yes, if you have a biologist account membership you can review edit save and validate the reports. if you are a medical doctor, you receive a notification once the report is validated by the biologist.
How many genes are covered by OncoDEEP kit panel?
The panel is composed of 638 genes, reporting genomic alterations (SNV, insertion, deletion, CNV) and complex genomic signature (HRD, MSI and TMB). OncoDEEP panel also looks at the introns of ALK/ROS1/RET/MET.
Beside that, OncoDEEP panel also covers 22 drivers genes (11 genes fusion and 9 unusual splicing) such as
Does OncoDEEP DNA panel look at the introns of ALK/ROS1/RET/MET?
It is because genomic breakpoints of fusion genes usually occur in the intronic regions. These 4 genes are especially important for NSCLC patients and being able to detect these gene fusions can help identify FDA-approved drug for NSCLC patients! As we know getting sufficient sample biopsy is a great challenge for NSCLC, hence we have designed our DNA panel to look at the intronic regions of these 4 genes just in case RNA sequencing cannot be done due to lack of tissue sample.
What is an 'Alpha List'?
Every type of cancer has a list of important variants and genes. These variants are reported in our report starting from a threshold of 3% instead of 10%. In that case, we are sure that we don’t miss any important variant. The client can add a variant on this list after a discussion with the scientific team.
What quality controls are in place to manage the data in OncoKDM?
Besides providing labs with QC data on sample quality such as read length and read quality, OncoKDM also offers genomic information at both the sample and gene levels.
At the sample level, this includes:
- Amount of reads
- Mean reads
- Coverage uniformity
- Exons with coverage greater than 100x
- Mean coverage
At the gene level, OncoKDM provides:
- Mean coverage
- Total amount of exons
- Mean coverage and uniformity by exons
Additionally, labs can access an extensive QC view containing detailed QC data
